Eur Neuropsychopharmacol. 2025 Jul:96:17-27.
DOI: 10.1016/j.euroneuro.2025.05.004. Epub 2025 May 22. PMID: 40408832
Vincenzo Oliva, Chiara Possidente , Giuseppe Fanelli, Katharina Domschke, Alessandra Minelli, Massimo Gennarelli, Paolo Martini, Marco Bortolomasi, Alessio Squassina, Claudia Pisanu, Siegfried Kasper, Joseph Zohar, Daniel Souery, Stuart Montgomery, Diego Albani, Gianluigi Forloni, Panagiotis Ferentinos, Dan Rujescu, Julien Mendlewicz, Bernhard T Baune; European College of Neuropsychopharmacology (ECNP) Pharmacogenomics & Transcriptomics Network; Eduard Vieta, Alessandro Serretti, Chiara Fabbri
In this original research study, the authors applied a cutting-edge methodology to predict the proteome plasma levels in more than 3,500 major depressive patients. Leveraging this dataset, the authors studied the association of such protein predicted levels with non-response, non-remission, and treatment-resistant depression (TRD) in this cohort. Results identified several nominal associations between specific proteins and these treatment-related variables and suggested that immune-inflammatory and neuroplastic mechanisms could play a key role in treatment response in major depression.
Read more here.
